home > pmps > autumn 2019 > exploring asia
Pharmaceutical Manufacturing and Packing Sourcer

Exploring Asia

As a region, Asia is home to 60% of the world’s population, which automatically makes it the largest healthcare opportunity in the world. While Japan has been on the industry radar for decades, China is now emerging as a growing source of opportunity for the industry. Driven by pro-innovation and pro-biotechnology policy trends, including drug regulatory reform and intellectual property rights protection, China is becoming a key destination for biopharmaceutical companies globally (1).

Within Asia, China and Japan are the two powerhouse economies and prescription markets, accounting for approximately 20% of global pharma spending. According to healthcare consulting firm IQVIA, China alone is expected to contribute $37 billion of the global prescription growth by 2022, covering 13% of the growth total and topping $160 billion in annual pharma spending (see Table 1, page 14). The US is supposed reach $600 billion of yearly market value by 2022 – that represents a $133 billion increase.

Currently, Asia accounts for 30% of all pharma spending globally. With rapid urbanisation and improved healthcare services, that figure is expected to increase as the region’s healthcare burden rises, especially with respect to chronic disease treatment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Zdenek Pecený studied Finance and Financial Services at the University of Finance and Administration in Prague and has 10 years of experience for various media outlets specialising in finance and business points of view. Zdeněk is based between London and Prague and has worked as a freelance journalist for three years while travelling and networking, gaining a greater understanding of attitudes of people and governments, particularly in business and healthcare.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

Industry Events

Pharmapack Europe 2020

5-6 February 2020, Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France

More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement